platinum has been researched along with B-Cell Chronic Lymphocytic Leukemia in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Croon-de Boer, F; Derks, IA; Eldering, E; Kater, AP; Mulkens, CE; Suo, G; Tonino, SH; van Laar, J; van Oers, MH; Wang, JY | 1 |
1 other study(ies) available for platinum and B-Cell Chronic Lymphocytic Leukemia
| Article | Year |
|---|---|
Induction of TAp73 by platinum-based compounds to overcome drug resistance in p53 dysfunctional chronic lymphocytic leukemia.
Topics: Antigens, Surface; Antineoplastic Agents; Apoptosis; Apoptosis Regulatory Proteins; BH3 Interacting Domain Death Agonist Protein; Biomarkers; Cell Cycle; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Proliferation; Cisplatin; Cyclin-Dependent Kinase Inhibitor p21; DNA-Binding Proteins; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Gene Knockdown Techniques; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymph Nodes; Nuclear Proteins; Platinum; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-abl; Tumor Protein p73; Tumor Suppressor Protein p53; Tumor Suppressor Proteins | 2015 |